17 news items
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
SNGX
14 Jun 24
of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
SNGX
STSS
7 Jun 24
(NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).For further
Soligenix Announces Reverse Stock Split
SNGX
31 May 24
Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
SNGX
29 May 24
of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
SNGX
24 May 24
Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA
b8ty3vvp391895835wmsw8klq8v1g22x1mmsqxf7qvhubz
SNGX
23 May 24
Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA
88ejzsksn93sdug8hf31emkm4tslz iyyi2emktloudx3z44dm
SNGX
21 May 24
Advanced Research and Development Authority (BARDA). For more information about Soligenix, Inc., please visit the company's website
zgk5 8ufakd
SNGX
21 May 24
or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts
17dn2 x3b
SNGX
20 May 24
of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority
a6a8838nr4jp72u5r0rftyk sg4uy9p088ayng
SNGX
16 May 24
of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA
o822suezfzynncro t28o770139
SNGX
10 May 24
.
Research and development expenses were $1.1 million as compared
cjoak lg25fg60ilbfgmr7
SNGX
6 May 24
Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further
mj48 bhpc15ux9bacxh6jvnbbx36tot20i9r9dpuffd7l
SNGX
25 Apr 24
Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA
t44wn7me28w0y jtg16btwxn7n6r654y1y1nd4wk61
SNGX
18 Apr 24
of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the Company's research and development
dilo3obxvjedewvt59
SNGX
15 Apr 24
Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc
ly9vwg8b0 ilikndl60akhmx1f87ixj8cjt
SNGX
11 Apr 24
Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc
dgbe0q4xn2g2ow c7g8vof26yfqxg8miuw57xay
SNGX
3 Apr 24
of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority
- Prev
- 1
- Next